Abbott Labs wrongly pushed Depakote for dementia care, will pay $1.5 billion

Share this article:
Nursing homes will be subject to escrow for all civil monetary penalties, CMS announces
Nursing homes will be subject to escrow for all civil monetary penalties, CMS announces
Abbott Laboratories has pleaded guilty and agreed to pay $1.5 billion over allegations that it promoted the anti-seizure drug Depakote for uses that were not approved by the Food and Drug Administration.

The company systematically promoted off-label use of the medication as a dementia treatment for nursing home residents. Abbott also paid kickbacks to physicians and long-term pharmacists to encourage its use, according to court records.

At a news conference Monday, U.S. Attorney Timothy Heaphy said the practice went beyond questionable practices by “some rogue sales representatives.” In fact, top officials at Abbott knew about and encouraged the misleading practice from 1998 to at least 2006.

The case includes a criminal fine and forfeiture of $700 million and civil settlements with the federal government and states totaling $800 million. The company also agreed to enter a five-year probationary period. Depakote is an anti-seizure and mood-stabilizing drug that is routinely prescribed for bipolar disorder.

Share this article:

More in News

Hospitals slap the government with lawsuits over 'two-midnight' policy to reduce observation stays

Hospitals slap the government with lawsuits over 'two-midnight' ...

The American Hospital Association and other hospital groups have sued the federal government over the so-called "two-midnight rule," which was designed in part to ease access to skilled nursing services. ...

Government would pay seniors to create advanced directives under Senate bill

Medicare beneficiaries would be paid to create advance directives and store them in an easy-access system if a recently proposed Senate bill were to become law.

MS patients less tense and pessimistic in nursing homes than at home, ...

Nursing home residents with severe multiple sclerosis report being less tense and pessimistic than similar individuals receiving care at home, according to recently published research findings.